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Abstract
As a continuation of our earlier studies on the lithiation-based synthesis of 8-methoxy-, 8-fluoro- and 8-chloro-3,4-dihydroisoquinoline, 
a similar approach was investigated for the preparation of the 8-diisopropylcarbamoyl congener. The corresponding N-pivaloyl 
phenylethylamine key intermediate was prepared via four new bifunctional intermediates in high overall yield. Lithiation of this 
intermediate followed by quenching with dimethylformamide led to a mixture: beside the desired compound containing the formyl 
moiety in the common ortho position of the two aromatic substituents, the isomer formylated in the other ortho position of the 
carbamoyl moiety was surprisingly obtained as the major product. The crude mixture could finally be transformed under acidic 
conditions to the target compound, 8-diisopropylcarbamoyl-substituted 3,4-dihydroisoquinoline, albeit in a low yield.
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1 Introduction
Isoquinolines and their partly saturated derivatives 
(i.e., dihydro- and tetrahydroisoquinolines) represent an 
important family of natural and synthetic compounds 
exhibiting biological activity. The significance of 8-sub-
stituted congeners is also demonstrated by the marketed 
antidepressant drug nomifensine (1, Fig. 1), a norepi-
nephrine–dopamine reuptake inhibitor that was launched 
as an antidepressant drug exhibiting no sedative effects 
[1]. Furthermore 1,8-disubstituted 1,2,3,4-tetrahydroiso-
quinolines (2, Fig. 1) proved to be potent calcium channel 
blockers synthesized for the treatment of chronic pain [2].
The observed biological activity of isoquinoline deriv-
atives substituted at position 8 of the aromatic ring initi-
ated a work at our laboratory aiming at the development of 
efficient synthetic methods for the preparation of 8-substi-
tuted 3,4-dihydroisoquinolines and for their further trans-
formation to various 8-substituted and 1,8-disubstituted 
1,2,3,4-tetrahydroisoquinolines. A comprehensive liter-
ature search revealed that the syntheses of tetrahydroiso-
quinolines bearing a single substituent on the benzene ring 
at position 8 necessitate various synthetic solutions that 
cannot be generalized. These literature approaches were 
summarized in our recent publications [3, 4].
We anticipated that N-pivaloyl-phenylethylamines 
exhibiting a directed metalation group (DMG) in the meta 
position could be suitable starting compounds for the 
elaboration of a general procedure, due to a regioselective 
lithiation in the common ortho position of the two 
aromatic substituents. As a first example, a short and 
efficient synthesis of 8-methoxy-3,4-dihydroisoquinoline 
(3a) was reported [5]. Lithiation of N-pivaloyl-3-
methoxyphenylethylamine (4a) with butyllithium 
(BuLi) in diethyl ether (DEE) at ambient temperature 
occurred at the common ortho site of the substituents 
(5a), and subsequent treatment with dimethylformamide 
(DMF) led to formyl derivative 6a (Scheme 1). Later, 
we succeeded in extending the reaction sequence to 
Fig. 1 Structure of antidepressant drug nomifensine (1) and drug 
candidates with calcium-channel blocking activity (2)
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N-pivaloyl-3-fluorophenylethylamine [3]. In the metalation 
step of 4b with BuLi, significant modifications had to be 
introduced. It was performed at −78 °C in order to prevent 
aryne formation by LiF elimination. Due to the poor 
solubility of compound 5b in DEE at this low temperature, 
tetrahydrofuran (THF) was used as the solvent. Subsequent 
quenching with DMF afforded formyl derivative 6b.
The easy availability of compounds 6 allowed the syn-
theses of 8-substituted-isoquinolines simpler than hith-
erto known. Acid-catalyzed cyclization of compounds 6 
accompanied by the loss of the pivaloyl moiety resulted in 
the corresponding 8-substituted 3,4-dihydroisoquinolines 
3, which are suitable starting compounds for the prepara-
tion of a wide variety of 8-substituted-isoquinolines and 
1,2,3,4-tetrahydroisoquinolines.
In continuation of these studies, we decided to extend 
this approach to the synthesis of 8-chloro-3,4-dihydroiso-
quinoline (3c, Scheme 2). According to our earlier studies 
in other families of compounds [6-8] and to other literature 
analogies, [9-11] a complimentary directing effect of the 
two substituents is expected in the lithiation reaction of 
N-pivaloyl-3-chlorophenylethylamine (4c). To our sur-
prise, lithiation of N-pivaloyl-3-chlorophenylethylamine 
(4c) with BuLi in THF at −78 °C, followed by treatment 
with DMF gave a product mixture formylated rather in the 
benzylic position of the side chain (7) than at the required 
ring position (6c, Scheme 2), with a molar ratio 2.5 : 1 for 
7 and 6c, respectively [4]. Acidic treatment of this crude 
mixture afforded target compound 3c with only 9 % over-
all yield for the two steps.
2 Results and discussion
The aim of the present study was to investigate the extensibil-
ity of the simple isoquinoline synthesis for derivatives exhib-
iting a carboxylic acid or carboxylic acid derivative moiety, 
as a versatile functional group, at position 8. The key issue 
is whether we can carry out a regioselective lithiation at the 
common ortho site of the corresponding starting compound. 
Scheme 1 Synthesis of 8-methoxy- (3a) and 8-fluoro-3,4-dihydroisoqunoline (3b)
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Scheme 2 Lithiation of N-pivaloyl-3-chlorophenylethylamine (4c) with BuLi
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There are many options that can be considered when select-
ing the suitable carboxylic acid derivative DMG in the meta 
position of N-pivaloylphenylethylamine. The carboxylic acid 
group itself is an ortho director in lithiation reactions [12]. 
However, it seems to be unfavorable for us, because a double 
deprotonation of the starting compound prior to the lithiation 
reaction is expected to give rise to the formation of a poorly 
soluble dianion. A similar problem may occur in the case 
of secondary amide DMG’s [13]. Tertiary amides are also 
powerful DMG’s. N,N-Diethylbenzamide requires the use of 
sec-BuLi in the metalation reaction in order to avoid ketone 
formation. [14, 15] Beak et al. reported ortho-lithiation of 
N,N-diisopropylbenzamides with BuLi/TMEDA at −78 °C 
[16]. In the course of our efforts to synthetize variously 
substituted phthalides we succeeded in performing similar 
reactions in the absence of TMEDA [7, 17]. Based on this 
experience we decided to apply N-pivaloylphenylethylamine 
substituted with N,N-diisopropylcarbamoyl group at the 
meta position (4d) in our study.
Contrary to 3-methoxy, 3-fluoro- and 3-chloropheny-
lethylamine, the 3-diisopropylcarbamoyl analogue (8, 
Scheme 3) is not commercially available, thus it was 
synthesised starting from 3-methylbenzoic acid (9) in 
4 steps (Scheme 3). First, acid 9 was treated with thi-
onyl chloride (SOCl
2
) and diisopropyl amine [(iPr)
2
NH] 
to give diisopropylamide 10, the bromination of which 
with N-bromosuccinimide (NBS) in the presence of a 
catalytic amount of azobisisobutyronitrile (AIBN) fur-
nished bromomethyl derivative 11. Nucleophilic sub-
stitution with sodium cyanide (NaCN) and subsequent 
catalytic hydrogenation of nitrile 12 with Raney nickel 
(Ra-Ni) in methanolic ammonia resulted in phenylethyl-
amine 8 that was acylated with pivaloyl chloride (PivCl) 
in the presence of triethylamine (Et
3
N) giving rise to the 
formation of key intermediate 4d.
Unfortunately, lithiation of 3-diisopropylcarbamoyl 
N-pivaloyl derivative 4d under the conditions applied for the 
3-fluoro and 3-chloro analogue (BuLi in THF at −78 °C) fol-
lowed by treatment with DMF did not take place in a regi-
oselective manner. LC-MS analysis of the complex mix-
ture indicated that, beside some unidentified components 
and the expected formyl compound 6d, another compound 
was detected as the major isomer (Scheme 4). Upon analogy 
with the lithiation of N-pivaloyl-3-chlorophenylethylamine 
Scheme 3 Preparation of N-pivaloyl key intermediate 4d
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Scheme 4 Transformation of N-pivaloyl key intermediate 4d to 3,4-dihydroisoquinoline derivative 3d
632|Hargitai et al.Period. Polytech. Chem. Eng., 63(4), pp. 629–635, 2019
(4c, Scheme 2), this major product was thought to be the 
derivative formylated in the benzyl position of side chain. 
Nonetheless, after work-up of the crude mixture by flash 
chromatography, the pending compound surprisingly proved 
to be derivative 13 that contains a formyl moiety in the ste-
rically less hindered ortho position of the diisopropylcarba-
moyl group. The structure of 13 was determined by detailed 
NMR studies (HSQC, HMBC, NOESY).
Despite all our efforts (use of 2 or 3 eq BuLi in THF at 
−78 °C and at −40 °C with various reaction times; reac-
tion with 3 eq BuLi in diethyl ether at 0 °C and −78 °C; 
lithiation with 3 eq s-BuLi in THF at −78 °C) to find opti-
mized reaction conditions, the ratio of 6d in the mixture 
could not be increased, and 6d could not be isolated in 
a pure form. Nevertheless, acidic treatment of the crude 
mixture obtained after the lithiation step finally afforded 
the 8-diisopropylcarbamoyl-substituted 3,4-dihydroiso-
quinoline target compound (3d), albeit in a low yield (3 % 
calculated for 4d, Scheme 4).
3 Conclusion
The aim of the present study was the elaboration of a syn-
thetic route of 8-diisopropylcarbamoyl-substituted 3,4-dihy-
droisoquinoline, based on the directed ortho-lithiation of 
the N-pivaloyl phenylethylamine derivative containing a 
diisopropylcarbamoyl moiety in the meta position. In spite 
of the presence of two DMG groups meta to each other, 
the lithiation did not preferably take place in the common 
ortho position. Thus, a mixture was obtained containing 
the desired regioisomer 6d as a minor component. Finally, 
the crude mixture could be transformed to the novel sub-
stituted 3,4-dihydroisoquinoline 3d in low yield. The new 
bifunctional intermediates 4d, 8, 11 and 12 can be applied 
as versatile building blocks in the synthesis of other types 
of compounds, too, so the significance of the synthetic route 
described above goes beyond synthesis of compound 3d.
4 Experimental section
All melting points were determined on a Büchi B-540 
(Flawil, Switzerland) capillary melting point apparatus 
and are uncorrected. IR spectra were obtained on a Bruker 
ALPHA FT-IR spectrometer (Billerica, MA, USA) in KBr 
pellets or as a film. 1H NMR, 13C NMR, HSQC, HMBC, 
NOESY and DEPTQ spectra were recorded at 295 K on 
a Bruker Avance III HD 600 (Billerica, MA, USA) (600 
and 150 MHz for 1H and 13C NMR spectra, respectively) 
or at ambient temperature on a Bruker Avance III 400 
(Billerica, MA, USA; 400 and 100 MHz for 1H and 13C 
NMR spectra, respectively) spectrometer. CDCl
3
 was used 
as the solvent and tetramethylsilane (TMS) as the internal 
standard. Chemical shifts (δ) and coupling constants (J) 
are given in ppm and in Hz, respectively. Mass spectra 
were recorded on a Bruker O-TOF MAXIS Impact mass 
spectrometer (Billerica, MA, USA) coupled with a Dionex 
Ultimate 3000 RS HPLC (Sunnyvale, CA, USA) system 
with a diode array detector. The reactions were followed 
by analytical thin-layer chromatography on silica gel 60 
F
254
 (Darmstadt, Germany) and HPLC-MS on a Shimadzu 
LC-20 HPLC equipment (Kyoto, Japan). Purifications by 
flash chromatography were performed applying a Teledyne 
Isco Combiflash® Rf system (Thousand Oaks, CA, USA) 
with Redisep® Rf silica flash columns using a hexane–
ethyl acetate (EtOAc) or a dichloromethane (DCM)–meth-
anol (MeOH) solvent system. Purification by preparative 
HPLC was carried out using Phenomenex  Gemini-NX 
C18 column (Torrance, CA, USA, 50×250 mm, dp=10 µm, 
CV=252 mL). All reagents were purchased from commer-
cial sources. Compounds 9 and 10 are known in the liter-
ature, while compounds 3d, 4d, 8, 11, 12, 13 are new, and 
are characterized below.
3-Methyl-N,N-bis(propan-2-yl)benzamide (10). 
SOCl
2
 (40.3 mL, 66.1 g, 555 mmol) was added to a solu-
tion of 3-methylbenzoic acid (9, 30.2 g, 222 mmol) in tol-
uene (40 mL). After stirring for 4 h at 50 °C, the solvent 
and SOCl
2
 were distilled under reduced pressure. The res-
idue was dissolved in toluene (350 mL), and treated with 
(iPr)
2
NH (62.2 mL, 44.9 g, 444.1 mmol), and the reaction 
mixture was cooled with an ice-water bath. After stirring for 
2 h at room temperature, the reaction mixture was diluted 
with water (50 mL). The layers were separated and the aque-
ous layer was extracted with toluene (2×30 mL). The com-
bined organic layer was dried over MgSO
4
. The solvent was 
evaporated to afford the title compound (43.5 g, 90 %) as a 
pale yellow solid. Mp 59−60 °C (toluene), lit. mp 59–60 °C 
[18]. IR (KBr): ν 2998, 1631, 1340 cm−1. 1H NMR (600 MHz, 
CDCl
3
): δ 7.25 (t, J = 7.5 Hz, 1H), 7.17 (d, J = 7.5 Hz, 1H), 
7.12 (s, 1H), 7.08 (d, J = 7.5 Hz, 1H), 3.86 (br, 1H), 3.50 (br, 
1H), 2.36 (s, 3H), 1.54 (br, 6H), 1.13 (br, 6H) ppm. 13C NMR 
(150 MHz, CDCl
3
): δ 171.16, 138.86, 138.21, 129.22, 128.19, 
126.17, 122.36, 50.79, 45.65, 20.65 ppm. HRMS calcd. for 
C
14
H
22
NO+ ([M+H]+): 220.1696, found 220.1695. Spectral 
data are in accord with the literature [18]. 
3-(Bromomethyl)-N,N-bis(propan-2-yl)benzamide 
(11). AIBN (2.80 g, 17.0 mmol) and NBS (36.0 g, 202.2 
mmol) were added to a solution of 10 (34.0 g, 155.3 mmol) 
in acetonitrile (220 mL). After stirring for 3 h at 80 °C, the 
Hargitai et al.
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solvent was evaporated. The residue was purified by flash 
chromatography (8–20 % EtOAc in hexane) to afford the 
title compound (30.8 g, 67 %) as a yellow oil. IR (film): ν 
2969, 1631, 1341 cm−1. 1H NMR (600 MHz, CDCl
3
): δ 7.39 
(dt, J1 = 7.5 Hz, J2 = 1.5 Hz, 1H), 7.36 (t, J = 7.5 Hz, 1H), 
7.35 (t, J = 1.5 Hz, 1H), 7.24 (dt, J1 = 7.5 Hz, J2 = 1.5 Hz, 
1H), 4.49 (s, 2H), 3.83 (br, 1H), 3.52 (br, 1H), 1.54 (br, 6H), 
1.15 (br, 6H) ppm. 13C NMR (150 MHz, CDCl
3
): δ 170.27, 
139.40, 138.12, 129.17, 128.53, 126.36, 125.52, 50.99, 
45.85, 32.89, 20.68 ppm. HRMS calcd. for C
14
H
21
BrNO+ 
([M+H]+): 298.0801, found 298.0801.
3-(Cyanomethyl)-N,N-bis(propan-2-yl)benzamide 
(12). NaCN (6.60 g, 135.6 mmol) was added to a solution 
of 11 (20.2 g, 67.8 mmol) in DMF (100 mL). After stirring 
for 4 h at 60 °C, water (40 mL) was added, and the result-
ing mixture was extracted with EtOAc (3×150 mL). The 
combined organic layer was dried over MgSO
4
 and fil-
tered. The solvent was distilled, and the residue was puri-
fied by flash chromatography (10–70 % EtOAc in hexane) 
to afford the title compound (13.7 g, 83 %) as a pale yel-
low oil. IR (film): ν 2970, 1628, 1343 cm−1. 1H NMR (600 
MHz, CDCl
3
): δ 7.41 (t, J = 7.5 Hz, 1H), 7.35 (d, J = 7.5 
Hz, 1H), 7.29 (s, 1H), 7.27 (d, J = 7.5 Hz, 1H), 3.81 (br, 
1H), 3.77 (s, 2H), 3.53 (br, 1H), 1.54 (br, 6H), 1.16 (br, 
6H) ppm. 13C NMR (150 MHz, CDCl
3
): δ 169.96, 139.84, 
130.38, 129.32, 128.11, 125.29, 125.19, 117.49, 50.96, 45.92, 
23.52, 20.65 ppm. HRMS calcd. for C15H21N2O+ ([M+H]+): 
245.1648, found 245.1650.
3-(2-Aminoethyl)-N,N-bis(propan-2-yl)benzamide 
(8). 12 (12.7 g, 52.0 mmol) was hydrogenated in metha-
nolic NH
3
 solution (250 mL) at 25 °C using H
2
 at 10 bar 
and Ra-Ni (4.60 g, ca. 30 % water content, ca. 78 mmol) 
catalyst for 4 h. After filtration, the solvent was evapo-
rated and the residue was purified by flash chromatog-
raphy (2–10 % MeOH in DCM) to afford the title com-
pound (11.1 g, 86 %) as a pale yellow oil. IR (film): ν 3441, 
3358, 2968, 1629, 1341 cm−1. 1H NMR (600 MHz, CDCl
3
): 
δ 7.33 (t, J = 7.5 Hz, 1H), 7.24 (d, J = 7.5 Hz, 1H), 7.20 
(s, 1H), 7.15 (d, J = 7.5 Hz, 1H), 3.84 (br, 1H), 3.51 (br, 
1H), 3.03 (t, J = 6.9 Hz, 2H), 2.86 (t, J = 6.9 Hz, 2H), 
1.53 (br, 6H), 1.13 (br, 6H) ppm. 13C NMR (150 MHz, 
CDCl
3
): δ 171.22, 139.48, 138.75, 129.27, 128.73, 126.16, 
123.45, 50.94, 45.85, 42.43, 37.85, 20.63 ppm. HSQC (145 
Hz): 7.33−128.73, 7.24−123.46, 7.20−126.16, 7.15−123.46, 
(3.84, 3.51)−(50.94, 45.85), 3.03−42.43, 2.86−37.85, (1.53, 
1.13)−20.63. HMBC (8 Hz, 145 Hz): 7.33−(139.48, 138.7), 
7.24−(126.16, 123.46, 37.85), 7.20−(171.22, 129.27, 123.46, 
37.85), 7.15−(171.22, 129.27, 126.16), 3.03−(37.85, 139.84), 
2.86−(139.48, 129.27, 126.16, 42.43). HRMS calcd. for 
C15H25N2O+ ([M+H]+): 249.1961, found 249.1961.
3 -[2 - (2 ,2 -Dimethylpropanamido)ethyl]-N, N-
bis(propan-2-yl)benzamide (4d). Pivaloyl chloride (5.20 
mL, 5.10 g, 42.6 mmol) in DCM (50 mL) was added to a 
solution of 8 (9.60 g, 38.7 mmol) and Et
3
N (6.50 mL, 4.70 
g, 46.6 mmol) in DCM (100 mL) at 0 °C. After stirring 
for 1 h at room temperature, the mixture was washed with 
aqueous NaHCO
3
 solution (5 %, 3×25 mL). The organic 
layer was dried over MgSO
4 
and evaporated. The residue 
was recrystallized from heptane to afford the title com-
pound (12.0 g, 93 %) as a colorless solid. Mp 113−114 °C 
(heptane). IR (KBr): ν 3338, 2970, 1611 cm−1. 1H NMR (600 
MHz, CDCl
3
): δ 7.31 (t, J = 7.5 Hz, 1H), 7.18 (d, J = 7.5 Hz, 
1H), 7.17 (d, J = 7.5 Hz, 1H), 7.13 (s, 1H), 5.69 (br, 1H), 3.83 
(br, 1H), 3.51 (br, 1H), 3.48 (q, J = 7.0 Hz, 2H), 2.83 (t, J = 7.0 
Hz, 2H), 1.54 (br, 6H), 1.14 (br, 6H), 1.14 (s, 9H) ppm. 13C 
NMR (150 MHz, CDCl
3
): δ 178.41, 170.85, 139.50, 139.30, 
129.13, 128.61, 125.92, 123.59, 50.88, 45.78, 40.48, 38.61, 
35.52, 27.51, 20.67 ppm. COSY: 5.69−3.48−2.83. HSQC 
(145 Hz): 7.31−128.61, 7.18−129.13, 7.17−123.59, 7.13−125.92, 
(3.83, 3.51)−(50.88, 45.78), 3.48−40.48, 2.83−35.52, (1.54, 
1.14)−20.67, 1.14−27.51. HMBC (8 Hz, 145 Hz): 7.31−
(139.50, 139.30, 123.59), 7.13−(170.85, 129.13, 123.59), 3.48−
(178.41, 139.30, 35.52), 2.83−(139.50, 129.13, 125.82, 40.48), 
1.14−(178.41, 38.61, 27.51). HRMS calcd. for C
20
H
33
N
2
O
2
+ 
([M+H]+): 333.2537 found 333.2539.
5-[2-(2,2-Dimethylpropanamido)ethyl]-2-formyl-
N,N-bis(propan-2-yl)benzamide (13). A solution of BuLi 
(1.6 M in hexane, 5.6 mL, 9.0 mmol) was added to a solu-
tion of 4d (1.00 g, 3.00 mmol) in THF (15 mL) at −78 °C. 
After stirring for 2 h at −78 °C, DMF (1.40 mL, 1.30 g, 18.1 
mmol) was added. The mixture was stirred for 2 h. After 
warming to ambient temperature, the reaction mixture 
was diluted with a saturated aqueous solution of NH
4
Cl (10 
mL), and extracted with EtOAc (6 and 2×4 mL). The com-
bined organic layer was dried over MgSO
4
 and evaporated. 
The residue was purified by flash chromatography (5–30 % 
EtOAc in hexane). The appropriate fractions were collected 
and evaporated. The residue was triturated in hexane/DEE, 
and filtered to afford the title compound (159 mg, 15 %) as 
a colorless solid. Mp 99–101 °C (hexane/DEE). IR (KBr): ν 
3431, 1690, 1625 cm−1. 1H NMR (400 MHz, CDCl
3
): δ 10.05 
(br s, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.32 (dd, J1 = 8.0 Hz, J2 = 
1.6 Hz, 1H), 7.10 (d, J = 1.6 Hz, 1H), 5.72 (br t, J1 = J2 ~ 6 Hz, 
1H), 3.57 (m, 1H), 3.55 (m, 1H), 3.50 (br, 2H), 2.91 (t, J1 = J2 
= 7.0 Hz, 2H), 1.60 (br, 6H), 1.16 (s, 9H), 1.10 (br d, J = 6.5 
Hz, 6H) ppm. 13C NMR (150 MHz, CDCl
3
): δ 190.14, 178.64, 
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168.20, 146.53, 141.48, 130.76, 130.05, 129.27, 126.32, 51.25, 
46.16, 40.28, 38.68, 35.78, 27.52, 20.53 (br), 20.14 (br) ppm. 
HSQC: 10.05−190.14, 7.87−130.05, 7.32−129.27, 7.10−126.32, 
3.57−51.25, 3.55−46.16, 3.50−40.28, 2.91−35.78, 1.60−20.14, 
1.16−27.52, 1.10−20.53. HMBC (7 Hz, characteristic cross-
peaks): 10.05−(130.76, 130.0), 7.87−(190.14, 146.53, 141.48), 
7.32−35.78, 7.10−35.78, 3.55−168.20, 2.91−(146.53, 129.27, 
126.32, 40.28), 1.16−(178.64, 38.68, 27.52). Selective NOESY: 
2.91−(7.32, 7.10, 5.72, 3.50). HRMS calcd. for C
21
H
33
N
2
O
3
+ 
([M+H]+): 361.2486, found: 361.2490.
N,N-Bis(propan-2-yl)-3,4-dihydroisoquinoline-8-
carboxamide hydrochloride (3d). A solution of BuLi (1.6 
M in hexane, 7.50 mL, 12.05 mmol) was added to a solu-
tion of 4d (2.00 g, 6.02 mmol) in THF (25 mL) at −78 °C. 
After stirring for 1 h at −40 °C, DMF (2.80 mL, 2.64 g, 
36.14 mmol) was added at −78 °C. The mixture was stirred 
for further 1 h at −40 °C. After warming to ambient tem-
perature, the reaction mixture was diluted with a satu-
rated aqueous solution of NH
4
Cl (7 mL), and extracted 
with EtOAc (8 and 2×4 mL). The combined organic layer 
was washed with brine (4 mL), and dried over MgSO
4
. The 
solvents were evaporated, the residue was purified by flash 
chromatography (0–1 % MeOH in DCM). The appropri-
ate fractions were collected and evaporated. The residue 
was dissolved in DCM (15 mL) and aqueous HCl (15 %, 
35 mL) was added. The mixture was vigorously stirred for 
24 h at 25 °C. The aqueous layer was washed with DEE 
(10 mL), and the organic layer was extracted with water 
(5 mL). The combined aqueous layers were evaporated. 
To a vigorously stirred mixture of the residue in DCM (5 
mL) and water (2 mL), aqueous sodium carbonate solution 
(10 w/w %, 1 mL) was added. The layers were separated 
and the aqueous layer was extracted with DCM (1 mL). 
The combined organic layers were extracted with brine 
(2 mL), and dried over MgSO
4
. The solvent was evapo-
rated and the residue was purified by preparative HPLC 
(30 % acetonitrile in water + 50 mM ammonium acetate) 
to afford the title compound (41 mg, 3 %) as a yellow solid. 
Mp 117−119 °C (hexane/EtOAc). IR (KBr): ν 3452, 2965, 
1628 cm−1. 1H NMR (600 MHz, CDCl
3
): δ 8.41 (s, 1H), 7.35 
(t, J = 7.6 Hz, 1H), 7.15 (d, J = 7.6 Hz, 1H), 7.11 (d, J = 
7.6 Hz, 1H), 3.86 (m, 1H), 3.70 (m, 1H), 3.63 (sep, J = 6.8 
Hz, 1H), 3.54 (sep, J = 6.8 Hz, 1H), 2.76 (m, 2H), 1.60 (d, 
J = 6.8 Hz, 3H), 1.58 (d, J = 6.8 Hz, 3H), 1.11 (d, J = 6.8 
Hz, 3H), 1.10 (d, J = 6.8 Hz, 3H) ppm. DEPTQ: 168.55, 
157.33, 137.18, 137.07, 130.97, 127.33, 124.13, 123.64, 51.11, 
47.03, 46.10, 25.27, 20.65, 20.57, 20.51, 20.41. HSQC (145 
Hz): 8.41−157.33, 7.35−130.97, 7.15−127.33, 7.11−123.64, 
(3.68, 3.70)−47.03, 3.63−51.11, 3.54−46.10, 2.76−25.27, 
(1.60, 1.58)−(20.51, 20.41), (1.11−1.10)−(20.65, 20.57). 
HMBC (8 Hz, 140 Hz, characteristic cross-peaks): 8.41−
(137.18, 137.07, 124.13), 7.35−(137.18, 137.07), 7.15−25.27, 
7.11−168.55. HRMS calcd. for C16H24ClN2O+ ([M+H]+): 
259.1805, found: 259.1810. 
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